NL-OMON38738已完成4 期
An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued everolimus treatment - Everolimus roll-over protocol (CRAD001C2X01B)
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.Patient is currently enrolled in a Novartis-sponsored study receiving everolimus or everolimus plus Sandostatin LAR® and has fulfilled all their requirements in the parent study.
- •2.Patient is currently benefiting from the treatment with everolimus, as determined by the guidelines of the parent protocol.
- •3. Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.;Other protocol defined inclusion criteria may apply
排除标准
- •1.Patient has been permanently discontinued from everolimus study treatment in the parent study.
- •2.Patient is receiving everolimus in combination with unapproved or experimental treatments.;Other protocol defined exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigatorDisease corresponding to the Novartis-sponsored study the patient will be transitioning fromEUCTR2012-004707-12-NLovartis Pharma Services AG13
进行中（未招募）
1 期
Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigatorDisease corresponding to the Novartis-sponsored study the patient will be transitioning fromEUCTR2012-004707-12-CZovartis Pharma Services AG50
进行中（未招募）
1 期
Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigatorEUCTR2012-004707-12-ITOVARTIS FARMA18
进行中（未招募）
1 期
Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigatorDisease corresponding to the Novartis-sponsored study the patient will be transitioning fromEUCTR2012-004707-12-ESovartis Farmacéutica, S.A.13
招募中
1 期
Asciminib Roll-over Studychronic myelogenous leukemia (CML) or Philadelphia Chromosome positiveacute lymphoblastic leukemia (Ph+ ALL)MedDRA version: 21.1Level: PTClassification code: 10009013Term: Chronic myeloid leukaemia Class: 100000004864CTIS2023-507557-16-00ovartis Pharma AG284